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Prescription Drug Costs
Do research expenses justify eye-popping prices?
Recent high-profile Senate hearings have highlighteda phenomenon many Americans know well: thesoaring price of prescription drugs, some neededto keep patients alive. New blockbusters routinely
cost more than $100,000 for a course of treatment, and similar
“me too” drugs for the same conditions later launch at almost
identical prices. Drug manufacturers blame the rising cost of re-
search and development, but critics blame excessive profit-seeking
and exorbitant marketing budgets. Meanwhile, prices for some
common, decades-old generics also are rising as competition in
that part of the industry collapses. The price of the antibiotic tetra-
cycline, for example, rose more than 7,500 percent in two years.
A majority of Americans say keeping drug prices affordable should
be the top national health care priority, and all three remaining
presidential candidates have promised relief. To help slow the 
rising costs, states are introducing bills and ballot measures to 
require drug makers to disclose their actual costs and, in some
cases, cap prices.
Martin Shkreli, former CEO of Turing Pharmaceuticals,
invoked his 5th Amendment right not to testify at a
Feb. 4 congressional committee hearing examining
prescription drug price gouging. After acquiring the
rights to manufacture the life-saving generic drug
Daraprim, Turing raised its price by 5,000 percent.
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b ending the health care cost curve in the right directionwill require new mechanisms to control drug prices.Drug spending in the United States increased 12 per-
cent in 2014, faster than nearly every other health care spending
component and the highest rate in more than a decade. Overall,
Medicare spending grew 5.5 percent, but drug spending grew
16.9 percent, hardly a sustainable rate.
Medicare is the largest purchaser of drugs, with 39 million indi-
viduals enrolled in Part D plans that help pay for prescriptions. Yet
a recent study by Marc-André Gagnon and Sidney Wolfe reported
that the program pays 73 percent more than Medicaid and 80 per-
cent more than the Veterans Administration for brand-name drugs.
Both agencies negotiate with drug companies for price discounts.
The Medicare Drug, Improvement, and Modernization Act of
2003 created prescription drug coverage through the Medicare
Part D program but specifically prohibited Medicare from negoti-
ating lower prices for drugs. Calls to change this have gone un-
heeded. Some opponents to negotiating Medicare drug prices fall
back on hackneyed arguments that the pharmaceutical industry
has used for years whenever the issue has come up: that nego-
tiation would stymie innovation and limit access to medications.
Others question whether the government could successfully ne-
gotiate lower prices. But these arguments assume the govern-
ment cannot change and enforce laws to ensure the necessary
leverage for negotiating reasonable prices. The arguments also
violate the principle that prices should — and, in fact, must —
be subject to the free market when a patent expires.
To pretend that negotiation will discourage progress violates
every economic rule we know. Negotiation is how two parties
reach a mutually advantageous compromise. Plus, we know that
excess monopoly profits, from which Big Pharma [the Pharma-
ceutical Research and Manufacturers of America] has “suffered”
for decades, do not lead to greater research but rather to higher
dividends and greater market concentration through acquisition
of competitors, a guarantee of even more inflated prices.
Monopoly drug pricing, particularly in the Medicare program,
can only be called corporate welfare. The American public has
had enough. A national survey conducted by the Kaiser Family
Foundation in August 2015 reported that 83 percent believe
the government should directly negotiate drug prices for
Medicare beneficiaries. This is a step long overdue.no
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p residential candidates and members of Congress oftenrecommend having the government negotiate fordrug discounts on behalf of the Medicare program. 
Most recently, presumptive GOP presidential nominee
Donald Trump joined Vermont Sen. Bernie Sanders and Democ-
ratic front-runner Hillary Clinton in supporting negotiations.
The typical proposal is to allow the secretary of Health and
Human Services (HHS) to negotiate with prescription drug
manufacturers on behalf of the Medicare Part D program —
something banned by the so-called “noninterference” clause in
the 2003 Medicare Modernization Act. This idea is hardly new.
It arose during discussions over passage of the law, and the
Congressional Budget Office, Congress’ nonpartisan budget
analysis agency, noted at the time that getting rid of the non-
interference provision would have a negligible impact.
This is hardly surprising. Drug companies negotiate annually
with prescription drug insurance plans. Those plans go into the
negotiations with some strong leverage: a formulary, or list of
drugs offering the greatest overall value, that can be used to
favor a drug company’s products and millions of customers who
could be delivered to the drug company or, faced with too high
a price, its competitors. Adding HHS to the mix does not
change that leverage. Here’s how such a negotiation would go:
HHS Secretary: I’d like a discount on your prescription drugs.
Drug Manufacturer: What do you have to offer?
HHS Secretary: I can guarantee millions of senior citizens
as customers; shouldn’t I get a discount?
Drug Manufacturer: What is your formulary like?
HHS Secretary: I don’t have one. We can’t discriminate.
Drug Manufacturer: Sorry, the prescription drug plans
have already guaranteed us the customer base, promised to
treat our drugs favorably in the formulary, and we’ve given
them the discounts. What else have you got?
HHS Secretary: Uh, a used copy of healthcare.gov?
Drug Manufacturer: We are done here.
The private-sector prescription drug plans already have all
available market-based leverage. Of course, the government
can do one thing that the private sector can’t: impose price
controls. Thus, many suspect that a call to repeal the nonin-
terference clause is really just a stalking horse for price con-
trols. Price-fixing never works, will hurt innovation and restrict
the availability of valuable therapies.
Medicare Part D is not broken. It is the best-functioning
entitlement program, and adding secretarial negotiation would
be far from fixing it.
